Over the last decade, the mechanisms of action of MPN-driving mutations, as well as co-occurring mutations (ASXL1, EZH2, DNMT3A, TET2), in MPN disease initiation and progression have been extensively studied, in vitro and in murine models (21–30). This evidence concerns the gene ASXL1 and myeloproliferative neoplasm.